Table 1 Baseline characteristics of included trials
Trials/yr. | Designs/grade | Downs and Black score | Treatment | NO. of patients | Age (yr.)* | Male (%) | Tumor Multiplicity* | Tumor Size (cm)* | Location(n) | T Stage (n) Grade(n) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lateral | Other | Ta | CIS | T1 | PUNLMP | Low | High | |||||||||
Yang [11], 2014 | Retrospective, B | 18 | KTP TURBT | 28 32 | 45.3 42.5 | 78.6 78.1 | NR NR | N/A N/A | 22 17 | 6 15 | 8 7 | 0 0 | 20 25 | NR NR | NR NR | NR NR |
Tao [12], 2013 | Retrospective, C | 17 | HPS | 74 | 66.4 | 81.08 | 1.52 | 2.1 | 62 | 12 | 50 | 1 | 23 | 9 | 60 | 5 |
TURBT | 84 | 65.3 | 78.57 | 1.49 | 1.9 | 69 | 15 | 61 | 2 | 21 | 10 | 68 | 6 | |||
Liu [13], 2013 | Prospective, B | 20 | 2-micron | 64 | 67.1 | 71.9 | 2.8 | 1.3 | 24 | 40 | 37 | 0 | 27 | 11 | 46 | 7 |
TURBT | 56 | 66.3 | 71.4 | 2.7 | 1.2 | 21 | 35 | 34 | 0 | 22 | 10 | 41 | 5 | |||
Zhong [16], 2010 | Retrospective, C | 16 | 2-micron | 30 | 68.30 | NR | 1.53 | 2.23 | NR | NR | 23 | 2 | 5 | 4 | 21 | 5 |
HoLRBT | 25 | 65.76 | NR | 1.40 | 1.38 | NR | NR | 19 | 1 | 5 | 3 | 18 | 4 | |||
TURBT | 42 | 66.26 | NR | 1.45 | 1.54 | NR | NR | 30 | 4 | 8 | 7 | 26 | 9 | |||
Xishuang [14], 2010 | Prospective, B | 18 | HoLRBT | 64 | 72.5 | 81.3 | 2.0 | 1.85 | 25 | 39 | 36 | 5 | 23 | 5 | 39 | 20 |
TURBT | 51 | 74.5 | 78.4 | 1.9 | 1.74 | 20 | 31 | 30 | 4 | 17 | 4 | 33 | 14 | |||
Zhu [15], 2008 | Prospective, B | 17 | HoLRBT | 101 | NR | 78.2 | NR | NR | NR | NR | 67 | 5 | 34 | NR | NR | NR |
TURBT | 111 | NR | 82.9 | NR | NR | NR | NR | 70 | 7 | 41 | NR | NR | NR | |||
Muraro [17], 2005 | Retrospective, C | 16 | HoLRBT | 50 | 64.5 | 78 | N/A | NR | NR | NR | 43 | 0 | 7 | NR | NR | NR |
TURBT | 50 | 65.7 | 80 | N/A | NR | NR | NR | 46 | 0 | 4 | NR | NR | NR | |||